Enterprise Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Sussex Innovation Centre University of S...Phone Number
+44 1273234667Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Enterprise Therapeutics
Enterprise Therapeutics is discovering and developing new therapies that target the underlying mechanisms of mucus congestion in the lungs, one of the main causes of difficulty in breathing and increased risk of infection in respiratory diseases such as cystic fibrosis and COPD. Reducing mucus congestion will reduce the frequency of lung infections and improve quality of life. The Company's novel muco-regulatory therapies target ion channels TMEM16A and ENaC to increase the hydration and clearance of mucus. Enterprise has also identified novel targets and compounds that reduce mucus production, an approach that complements mucus hydration therapies. The Enterprise Therapeutics management team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The Company is backed by leading life science investors Epidarex Capital, Forbion Capital, IP Group, Novartis Venture Fund and Versant Ventures. In 2019 the company received funding froRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enterprise Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Enterprise Therapeutics launches new products
Earning: See what the market has to say on Enterprise Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Enterprise Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Enterprise Therapeutics
Funding: Get notified immidiatlly once Enterprise Therapeutics has new funding data
Enterprise Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Enterprise Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Enterprise Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Enterprise Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Enterprise Therapeutics
Compare insights from companies similar to Enterprise Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Enterprise Therapeutics
<$5M
1-10
Private
$77.7M
2014
N/A
Company Profile Activity
Activity Insights
Enterprise Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Enterprise Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Enterprise Therapeutics.
Enterprise Therapeutics financials insights
Gather financial insights about Enterprise Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$3.6M
2024
Series B
$74.1M
Enterprise Therapeutics Tech Stack
A closer look at the technologies used by Enterprise Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Enterprise Therapeutics News & Media
Enterprise Therapeutics Granted ‘Rare Pediatric Disease Designation’ in the US for Novel Cystic Fibrosis Investigational Therapy ETD001
BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced its novel cystic fibrosis (CF) investigational therapy, ETD001, has been granted ‘rare pediatric disease designation’ (RPD) in the US by the Food and Drug Administration (FDA).1 ETD001 is a low molecular weight compound with first-in-class potentialEnterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001
BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001. ETD001, a low molecular weight compound with first-in-class potential, targets the epithelial sodium channel (ENaC) in the airway epithelium to increase the hydrEnterprise Therapeutics Publishes Preclinical Profile of ETD001, a Novel Inhaled ENaC Blocker
BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1. The paper describes low doses of the ENaC blocker ETD001, Enterprise’s lead asset, enhancing airway mucus clearance with an exceptionally long duration of action in a sheep model.Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners. Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated. Alongside the
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Enterprise Therapeutics
Sign Up For FreeTo access detailed company insights
Enterprise Therapeutics is discovering and developing new therapies that target the underlying mechanisms of mucus congestion in the lungs, one of the main causes of difficulty in breathing and increased risk of infection in respiratory diseases such as cystic fibrosis and COPD. Reducing mucus congestion will reduce the frequency of lung infections... Read More
